Asset / Drug

FOLFOX8

Drug and asset intelligence for FOLFOX8 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Roche →

Recent signals(1)

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Roche — FOLFOX8

Key milestones include enrollment completion, interim results on progression-free survival, and overall survival rates.

June 17, 2026 · N/A

Indications

Colorectal Cancer →

Therapeutic areas

Colorectal Cancer →

Oncology →

Oncology · Colorectal Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.